Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, October 02, 2014
Technology Networks
 
Register | Sign in
Home Page
  News
Return

FDA Accepts Biogen Idec’s Biologics License Application

Published: Tuesday, May 14, 2013
Last Updated: Tuesday, May 14, 2013
Bookmark and Share
ELOCTATE™ has potential to provide long-lasting protection and markedly reduce treatment burden for patients.


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here


Scientific News
Monkey Antibodies Help Fight Virus
Details of monkey antibodies against chikungunya virus could help to fight the disease in humans.
Calixar and VirPath Develop an Innovative Manufacturing Process
A new antigens formulation against pandemic flu (A H1N1 virus) proved six times more effective than other vaccines.
New Approach To Arthritis Treatment
A new approach to arthritis treatment, which avoids unforeseen side-effects by delivering drugs exclusively to affected inflamed joints, has been developed by researchers at Queen Mary University of London.
A New Molecule Allows for an Increase in Stem Cell Transplants
A clinical study using UM171 and a new type of bioreactor developed for stem culture will be initiated in December 2014.
Novel Drug Targeting Leukemia Cells Enters Clinical Trial
Phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for CLL patients.
Salmonella - Why Live Vaccines May Be Most Effective
University of Cambridge researchers investigated the effectiveness of vaccines against Salmonella.
Intestinal Bacteria Needed for Strong Flu Vaccine Responses in Mice
Study demonstrate a dependency on gut bacteria for strong immune responses to the seasonal flu and inactivated polio vaccines.
Novel Immunotherapy Breast Cancer Vaccine
Vaccine Decreases Recurrence in HER2 Positive Breast Cancer Patients.
Cell ‘Memory’ Could be Key to Strengthen Vaccine Efficacy
Virginia Tech Carilion Research Institute scientists uncover immune system secret.
NIH-Led Scientists Discover HIV Antibody that Binds to Novel Target on Virus
The antibody, 35O22, prevents 62 percent of known HIV strains from infecting cells in the laboratory.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv